Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Denali Therapeutics ( (DNLI) ) just unveiled an update.
Denali Therapeutics has outlined key milestones for 2025, including the anticipated submission of a biologics license application for tividenofusp alfa for Hunter syndrome and preparations for its commercial launch. The company is also pursuing an accelerated approval pathway for DNL126 for Sanfilippo syndrome Type A. These efforts, along with expanding their portfolio through the TransportVehicleTM platform, aim to establish a broad franchise of enzyme replacement therapies, highlighting Denali’s commitment to addressing rare and common brain-impacting diseases.
More about Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company focused on developing therapeutics for neurodegenerative and lysosomal storage diseases. Based in South San Francisco, the company utilizes its TransportVehicleTM platform to facilitate the delivery of large molecules across the blood-brain barrier, targeting rare and common diseases.
YTD Price Performance: -8.35%
Average Trading Volume: 879,290
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.75B
Learn more about DNLI stock on TipRanks’ Stock Analysis page.
